Multiple Myeloma Clinical Trial
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Summary
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Eligibility Criteria
Inclusion Criteria:
Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
Have measurable disease at screening as defined by at least 1 of the following: a. Serum monoclonal protein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL); or b. Urine M-protein level >= 200 milligrams (mg)/24 hours; or c. Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at screening and immediately before the start of study treatment administration
A woman of childbearing potential must have a negative highly sensitive serum beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine or serum pregnancy test within 24 hours before the start of study treatment administration
Be willing and able to adhere to the lifestyle restrictions specified in the protocol, including adherence to the applicable immunomodulatory drug (IMiD) global Pregnancy Prevention Plan (PPP) or local PPP/Risk Evaluation and Mitigation Strategy (REMS) program
Exclusion Criteria:
Live, attenuated vaccine within 4 weeks before the first dose of study treatment
Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within the 14-day period before the start of study treatment administration
Active central nervous system (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
Known to be seropositive for human immunodeficiency virus
History of stroke or seizure within 6 months prior to the first dose of study treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 35 Locations for this study
Birmingham Alabama, 35294, United States
San Francisco California, 94143, United States
Denver Colorado, 80218, United States
Atlanta Georgia, 30322, United States
Indianapolis Indiana, 46202, United States
Westwood Kansas, 66160, United States
Saint Louis Missouri, 63110, United States
Hackensack New Jersey, 07601, United States
New York New York, 10029, United States
New York New York, 10065, United States
Charlotte North Carolina, 28204, United States
Pittsburgh Pennsylvania, 15232, United States
Nashville Tennessee, 37203, United States
Seattle Washington, 98109, United States
Milwaukee Wisconsin, 53226, United States
Fitzroy , 3065, Australia
Melbourne , 3004, Australia
Southport , 4215, Australia
Wollongong , 2500, Australia
Brussel , 1200, Belgium
Edegem , 2650, Belgium
Gent , 9000, Belgium
Leuven , 3000, Belgium
Lyon Cedex 8 , 69373, France
Nantes Cedex 1 , 44093, France
Pessac cedex , 33604, France
Rennes , 35000, France
TOULOUSE Cedex 9 , 31059, France
Groningen , 9713 , Netherlands
Maastricht , 6229 , Netherlands
Utrecht , 3584 , Netherlands
London , W1T 7, United Kingdom
Manchester , M20 4, United Kingdom
Oxford , OX3 7, United Kingdom
Surrey , SM2 5, United Kingdom
How clear is this clinincal trial information?